Romosozumab

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Romosozumab
   1. Pharmacist Assessment Report
   2. Romosozumab: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Romosozumab: Known uses and market status in Australia

Summary

The TxGNN deep-learning model produced candidate indications for Romosozumab, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. This page records the market status in Australia and the known uses found among the model’s candidates.

Quick overview

Item	Content
New predicted indications	None (all traceable model candidates are known uses)
Known uses among model candidates	0
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Australia Market Information

Licence	Product	Dosage form	Status
12301K	Evenity	Injection 105 mg in 1.17 mL single use p	Valid

Safety Considerations

• Knowledge-graph contraindication signals (not taken from label text): hypercalcaemia, nephrocalcinosis and phosphorus metabolism disease.
• Drug Interactions: 29 interactions were recorded. The detailed list covers 20 drugs:
  • Major: etelcalcetide.
  • Moderate:
    • Systemic corticosteroids, such as hydrocortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, budesonide, deflazacort and fludrocortisone.
    • Anti-angiogenic and oncology agents, such as bevacizumab, ramucirumab, axitinib, pazopanib, cabozantinib, regorafenib, dasatinib, lenalidomide and pomalidomide.

Label-based warnings and contraindications were not available for this report. Please refer to the TGA-approved Product Information (PI) for full safety information, including the cardiovascular warning and hypocalcaemia risk.

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---